Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Buy

A

Vertex Pharmaceuticals Inc (VRTX)

Pharmaceutical Preparations

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

50 NORTHERN AVENUE
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/31/1991

Market Cap

122,683,623,185

Shares Outstanding

257,680,000

Weighted SO

257,683,184

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

BMRN --.--%

SRPT --.--%

SGEN --.--%

ALNY --.--%

NTLA --.--%

EDIT --.--%

BEAM --.--%

DNA --.--%

BNTX --.--%

Beta

0.3920

Last Div

0.0000

Range

340.83-510.64

Chg

3.3300

Avg Vol

1220091

Mkt Cap

122683623185

Exch

NASDAQ

Country

US

Phone

617 341 6100

DCF Diff

-306.9531

DCF

781.7631

Div Yield

0.0000

P/S

11.8844

EV Multiple

-5722.9290

P/FV

8.3036

Div Yield %

0.0000

P/E

-250.4239

PEG

-28.1128

Payout

0.0000

Current Ratio

2.5207

Quick Ratio

2.2629

Cash Ratio

1.2912

DSO

58.5557

DIO

238.2451

Op Cycle

296.8008

DPO

85.4150

CCC

211.3858

Gross Margin

0.8643

Op Margin

-0.0380

Pretax Margin

0.0208

Net Margin

-0.0475

Eff Tax Rate

3.2818

ROA

-0.0243

ROE

-0.0291

ROCE

-0.0236

NI/EBT

-2.2818

EBT/EBIT

-0.5474

EBIT/Rev

-0.0380

Debt Ratio

0.0464

D/E

0.0632

LT Debt/Cap

0.0594

Total Debt/Cap

0.0594

Int Coverage

-17.8273

CF/Debt

-1.0114

Equity Multi

1.3626

Rec Turnover

6.2334

Pay Turnover

4.2733

Inv Turnover

1.5320

FA Turnover

5.8300

Asset Turnover

0.5128

OCF/Share

-3.6575

FCF/Share

-5.5242

Cash/Share

22.4545

OCF/Sales

-0.0914

FCF/OCF

1.5104

CF Coverage

-1.0114

ST Coverage

0.0000

CapEx Coverage

-1.9593

Div&CapEx Cov

-1.9593

P/BV

8.3036

P/B

8.3036

P/S

11.8844

P/E

-250.4239

P/FCF

-86.0455

P/OCF

-129.9605

P/CF

-129.9605

PEG

-28.1128

P/S

11.8844

EV Multiple

-5722.9290

P/FV

8.3036

DPS

0.0000

Latest Headlines (EST)

The Motley Fool May 24, 17:05 2 Monster Growth Stocks to Buy and Hold for 10 Years The Motley Fool Mar 08, 15:41 3 Magnificent Growth Stocks to Buy in March The Motley Fool Feb 15, 13:45 2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 The Motley Fool Feb 10, 22:56 Vertex's Revenue Surges but EPS Slips The Motley Fool Feb 09, 16:15 2 Biotech Stocks to Buy Hand Over Fist in February The Motley Fool Jan 25, 16:15 Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. The Motley Fool Dec 22, 17:25 This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? Benzinga Dec 22, 15:38 Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio? The Motley Fool May 25, 14:00 2 Biotech Stocks to Buy in May The Motley Fool Feb 29, 14:00 Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks? The Motley Fool Feb 29, 14:00 Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks? The Motley Fool Jan 23, 09:30 1 Setback and 1 Opportunity for CRISPR Therapeutics Stock The Motley Fool Jan 22, 14:23 A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist The Motley Fool Jan 22, 09:00 If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today The Motley Fool Jan 21, 07:15 2 Smart Growth Stocks to Buy Hand Over Fist in 2024 The Motley Fool Jan 20, 12:50 3 Unstoppable Growth Stocks That Can Make You Richer in 2024 The Motley Fool Jan 20, 12:50 3 Unstoppable Growth Stocks That Can Make You Richer in 2024 The Motley Fool Jan 20, 12:50 3 Unstoppable Growth Stocks That Can Make You Richer in 2024 The Motley Fool Jan 20, 12:50 3 Unstoppable Growth Stocks That Can Make You Richer in 2024 The Motley Fool Jan 20, 12:50 3 Unstoppable Growth Stocks That Can Make You Richer in 2024

Revenue Product Segmentation

a